Table 2.
Mean values and standard deviation of conventional GLS and AI-automated GLS at individual timepoints during trastuzumab therapy.
| T0 | T1 | T2 | T3 | T4 | T5 | |
|---|---|---|---|---|---|---|
| GLS (CON) | −20.1 ± 2.6 | −19.0 ± 2.8 | −18.8 ± 2.3 | −18.3 ± 2.3 | −19.1 ± 1.9 | −19.3 ± 2.5 |
| GLS (AI) | −19.0 ± 2.2 | −18.6 ± 1.8 | −18.2 ± 2.7 | −17.3 ± 3.2 | −18.1 ± 2.4 | −18.4 ± 2.0 |
| A4C (CON) | −20.0 ± 3.1 | −19.0 ± 3.2 | −18.9 ± 2.7 | −18.6 ± 3.0 | −19.1 ± 2.3 | −19.4 ± 2.6 |
| A4C(AI) | −19.8 ± 3.9 | −19.4 ± 4.0 | −18.5 ± 3.5 | −18.8 ± 3.7 | −19.3 ± 3.1 | −19.1 ± 3.1 |
| A2C CON) | −20.8 ± 2.9 | −19.2 ± 3.7 | −18.5 ± 4.1 | −18.8 ± 2.7 | −19.6 ± 2.4 | −20.0 ± 3.5 |
| A2C (AI) | −20.7 ± 4.2 | −19.2 ± 4.2 | −18.4 ± 3.9 | −18.1 ± 3.2 | −19.1 ± 4.4 | −19.7 ± 4.1 |
| A3C CON) | −19.6 ± 3.1 | −18.8 ± 3.8 | −18.8 ± 2.5 | −18.3 ± 2.9 | −19.3 ± 2.8 | −18.8 ± 3.3 |
| A3C (AI) | −15.3 ± 3.0 | −15.5 ± 2.0 | −15.7 ± 3.5 | −13.9 ± 3.7 | −15.5 ± 2.8 | −14.9 ± 3.7 |
| LVEF (CON) | 61.5 ± 4.6 | 59.8 ± 5.7 | 58.7 ± 6.6 | 58.5 ± 6.3 | 58.9 ± 5.7 | 59.5 ± 5.7 |
| LVEF (AI) | 63.4 ± 6.9 | 62.4 ± 6.7 | 58.8 ± 9.2 | 58.9 ± 8.7 | 58.9 ± 7.4 | 62 ± 6.0 |
Data are expressed as mean ± standard deviation.
AI, artificial intelligence; A4C, apical-four chamber; A2C, apical-two chamber; A3C, apical-three chamber; CON, conventional; GLS, global longitudinal strain; LVEF, left ventricular ejection fraction.